CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: CD74, also known as the invariant chain, participates in several key processes of the immune system, including antigen presentation, B-cell differentiation and inflammatory signaling. Despite being described more than 3 decades ago, new functions and novel interactions for this evolutionarily conserved molecule are still being unraveled. As a participant in several immunological processes and an indicator of disease in some conditions, it has potential as a therapeutic target. AREAS COVERED: The relationship between the structure of CD74 variants and their physiological functions is detailed in this review. The function of CD74 in several cell lineages is examined with a focus on the interactions with cathepsins and, in an inflammatory milieu, the pro-inflammatory cytokine macrophage migratory inhibitory factor. The role of CD74 signaling in inflammatory and carcinogenic processes is outlined as is the use of CD74 as a therapeutic target (in cancer) and tool (as a vaccine). EXPERT OPINION: CD74 has several roles within the cell and throughout the immune system. Most prominent amongst these are the complex relationships with MIF and cathepsins. Modulation of CD74 function shows promise for the effective amelioration of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MIF Signal Transduction Initiated by Binding to CD74
Leng, L., Metz, C. N., Fang, Y., Xu, J., Donnelly, S., Baugh, J., Delohery, T., Chen, Y., Mitchell, R. A., & Bucala, R. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030286 · Cited by 1,154
CD74 Is a Member of the Regulated Intramembrane Proteolysis-processed Protein Family
Becker-Herman, S., Arie, G., Medvedovsky, H., Kerem, A., & Shachar, I. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-04-0327 · Cited by 141 · cited 5×
“Interestingly, it was demonstrated that the CD74-ICD translocates to the nucleus where it elevates NF-kB activation [45].”
BackgroundInfluential
Cited by
Dysregulation of brain and choroid plexus cell types in severe COVID-19
Yang, A. C., Kern, F., Losada, P. M., Agam, M. R., Maat, C. A., Schmartz, G. P., Fehlmann, T., Stein, J. A., Schaum, N., Lee, D. P., et al. (2021) · Nature · doi:10.1038/s41586-021-03710-0 · Cited by 620
The biological function and significance of CD74 in immune diseases
Su, H., Na, N., Zhang, X., & Zhao, Y. (2017) · Inflammation Research · doi:10.1007/s00011-016-0995-1 · Cited by 306
CD74 and intratumoral immune response in breast cancer
Wang, Z.-Q., Milne, K., Webb, J. R., & Watson, P. H. (2017) · Oncotarget · doi:10.18632/oncotarget.8610 · Cited by 202
“CD74 has dual roles as a component of the MHC class II antigen presentation pathway and as a cytokine receptor [2], as well as intracellular effects on activation of transcription [3, 4].”
Role of MIF Cytokine/CD74 Receptor Pathway in Protecting Against Injury and Promoting Repair
Farr, L., Ghosh, S., & Moonah, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01273 · Cited by 166
MIF and CXCL12 in Cardiovascular Diseases: Functional Differences and Similarities
van der Vorst, E. P. C., Döring, Y., & Weber, C. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00373 · Cited by 57
Metadata
- Authors
- Borghese, F., & Clanchy, F. I.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2011-01-06
- Volume
- 15
- Issue
- 3
- Pages
- 237-251
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2113808060
- Cited by
- 174
- References
- 2
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.